Randomized trials have consistently demonstrated that EGFR-TKIs, such as erlotinib (ELTN), gefitinib, and afatinib feature better prognosis than conventional chemotherapy in distinct subgroup of advanced-stage NSCLC patients (Song et al., 2018). Here, EGFR is linked to non-small cell lung carcinoma.